Abstract: A process for manufacturing coated particles of &ggr;-aminobutyric acid analogue, whose lactam content by weight relative to the weight of &ggr;-aminobutyric acid analogue is less than 0.5% is disclosed. The process is characterized in that a coating solution of at least one polymer in an organic solvent is sprayed onto the particles of &ggr;-aminobutyric acid analogue.
Type:
Grant
Filed:
February 5, 2001
Date of Patent:
December 3, 2002
Assignee:
Societe Laboratoires des Products Ethiques - Ethypharm
Inventors:
Etienne Bruna, Edouard Gendrot, Charles Chauveau, Alain-Gilles Demichelis
Abstract: The present invention relates to a novel oral immediate-release morphine sulfate formulation in the form of microgranules. Each microgranule comprises a neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose, which represents 10 to 50% by weight of the morphine sulfate/binder mixture. The present invention also relates to a process for the preparation of these microgranules which is carried out entirely in aqueous medium on neutral support grains. The present invention finally relates to the pharmaceutical preparations comprising the microgranules according to the invention.
Type:
Grant
Filed:
February 16, 1999
Date of Patent:
November 19, 2002
Assignee:
Laboratoires des Produits Ethiques Ethypharm
Abstract: The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.
Type:
Grant
Filed:
September 8, 1999
Date of Patent:
October 1, 2002
Assignee:
Laboratoires Des Produits Ethiques Ethypharm
Abstract: The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixture of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules.
Type:
Application
Filed:
January 8, 2002
Publication date:
July 25, 2002
Applicant:
Ethypharm
Inventors:
Noureddine Nouri, Jean-Marc Zuccarelli, Etienne Bruna, Charles Chauveau
Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).
Type:
Grant
Filed:
January 11, 2001
Date of Patent:
May 7, 2002
Assignee:
Laboratoires des Produits Ethiques Ethypharm
Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.
Type:
Application
Filed:
November 16, 2001
Publication date:
May 2, 2002
Applicant:
Laboratoires Des Produits Ethiques Ethypharm
Inventors:
Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
Abstract: The invention concerns a method for making tablets with active principle sustained-release which consists in: preparing a fluid oil-in-water emulsion; spraying the resulting emulsion on a powder mixture containing at least the active principle; subjecting said treated powder to a compressing step, to obtain tablets.
Type:
Grant
Filed:
December 8, 2000
Date of Patent:
April 30, 2002
Assignees:
Gattefosse S.A., Ethypharm
Inventors:
Joseph Joachim, Pascal Prindirre, Nabil Farah
Abstract: A process for manufacturing coated particles of &ggr;-aminobutyric acid analogue, whose lactam content by weight relative to the weight of &ggr;-aminobutyric acid analogue is less than 0.5% is disclosed. The process is characterized in that a coating solution of at least one polymer in an organic solvent is sprayed onto the particles of &ggr;-aminobutyric acid analogue.
Type:
Application
Filed:
February 5, 2001
Publication date:
January 31, 2002
Applicant:
Societe Laboratoires des Produits Ethiques - Ethypharm
Inventors:
Etienne Bruna, Edouard Gendrot, Charles Chauveau, Alain-Gilles Demichelis
Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).
Type:
Grant
Filed:
November 25, 1998
Date of Patent:
May 8, 2001
Assignee:
Laboratories des Produits Ethiques Ethypharm
Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing tiagabine as active principle. The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids. These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the tiagabine contained in the spheroids following a possible compression step.
Type:
Grant
Filed:
November 23, 1998
Date of Patent:
October 31, 2000
Assignee:
Laboratoires des Produits Ethiques Ethypharm
Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing one or more active principles, which the exception of tiagabine.The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids.These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the active principle(s) following a possible compression step.
Type:
Grant
Filed:
November 23, 1998
Date of Patent:
June 20, 2000
Assignee:
Laboratoires des Products Ethiques Ethypharm
Abstract: According to the present invent, effervescent granules having a controllable rate of effervescence are provided. Such granules comprise an acidic agent, an alkaline agent, a hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process.
Abstract: The present invention relates to a galenic form of 5-nitroimidazole derivatives which is characterized in that it comprises a combination of microgranules of 5-nitroimidazole derivatives consisting, on the one hand, of gastroresistant microgranules and, on the other hand, of prolonged-release microgranules, the pharmaceutical compositions comprising them and the microgranules as intermediates in the preparation of the form according to the invention.
Type:
Grant
Filed:
January 11, 1995
Date of Patent:
August 27, 1996
Assignee:
Laboratoires Des Produits Ethiques Ethypharm
Abstract: The present invention relates to a stable formulation of omeprazole microgranules containing a neutral core consisting of sugar and starch, characterized in that it contains an active layer consisting of a dilution of omeprazole in mannitol in substantially equal amounts. It also relates to a process for producing such formulations.
Abstract: A process for preparing a controlled release medicine containing fenofibrate in an intermediate layer in the form of cyrstalline microparticles included within pores of an inert matrix prepared by a process involving the sequential steps of dampening said inert core with a solution based on said biner, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying before said solution based on said binder dissolves said fenofibrate microparticles and repeating said three steps in sequence until said intermediate layer is formed.
Abstract: The slow release preparation obtained by the method of the invention reduces the number of times the medicine needs to be taken per day, and also provides lower peaks of concentration in the blood after the medicine has been taken while simultaneously ensuring that the lowest concentration in the blood remains higher over a period of time.
Abstract: The slow release preparation obtained by the method of the invention reduces the number of times the medicine needs to be taken per day, and also provides lower peaks of concentration in the blood after the medicine has been taken while simultaneously ensuring that the lowest concentration in the blood remains higher over a period of time.